Poolbeg Pharma PLC (POLB) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Paul Begg Pharma PLC full year results investor presentation. Perhaps recording meeting investors will be in listen only mode. Questions are encouraged. You can be submitted at any time by the Q&A tab situated on the right hand corner of your screen to simply type in your question and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted and publish responses where appropriate to do so. Before we begin, we'd like to submit the following poll. I'd now like to hand you over to Jeremy Skillington, CEO. Good afternoon, sir. Good afternoon, and thank you for the introduction. I appreciate everybody joining us this late afternoon. Finally, a bit of a sunny Dublin. It's, you know, the bleak winter is over, and we're delighted here to be able to present on the back of our full year results announced this morning, a company update, a company presentation, and let you know where we are with, particularly, POD001, so again, appreciate you joining us this evening. And I'll be sharing presentation duties tonight with Liam Trimble, our principal scientist, who will talk more of the policy or zero-one clinical trial attributes. So just to give a setting, just a grounding, a reminder, Poolveg, we're a clinical stage company developing POG-001 that we believe has the potential to transform the lives of cancer patients by delivering these cancer immunotherapies, in particular, safely and locally. There's a lot of issues around cytokine release syndrome associated with cancer immunotherapies, and we believe we have a solution for that. We'll talk a little bit more about the scientific and medical rationale for that later on. We're also develo...